Ligand validation:4QAC

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 4QAC designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4QAC_NAG_A_303	29%	21%	0.175	0.834	1.72	1.61	4	3	0	0	100%	0.9333
4QAC_NAG_I_303	14%	77%	0.2	0.747	0.3	0.62	-	-	1	0	100%	0.9333
4QAC_NAG_E_301	10%	56%	0.199	0.698	0.44	1.24	-	1	0	0	100%	0.9333
4QAC_NAG_B_302	6%	19%	0.205	0.637	1.24	2.16	1	5	0	0	100%	0.9333
4QAC_NAG_J_301	5%	15%	0.296	0.711	0.89	2.81	-	7	0	0	100%	0.9333
4QAC_NAG_G_301	2%	70%	0.404	0.695	0.36	0.78	-	1	0	0	100%	0.9333
4QAC_NAG_D_303	2%	70%	0.278	0.537	0.37	0.78	-	1	0	0	100%	0.9333
4QAC_NAG_F_303	2%	26%	0.329	0.565	1.02	1.97	1	5	0	0	100%	0.9333
4QAC_NAG_H_302	1%	41%	0.349	0.523	0.59	1.68	-	6	0	0	100%	0.9333
5J5H_NAG_E_301	93%	70%	0.072	0.966	0.54	0.63	-	-	0	0	100%	0.9333
5J5I_NAG_J_301	80%	76%	0.082	0.929	0.26	0.67	-	-	0	0	100%	0.9333
7DJI_NAG_A_402	77%	57%	0.116	0.954	0.55	1.08	-	2	0	0	100%	0.9333
5J5G_NAG_E_302	57%	71%	0.148	0.924	0.44	0.68	-	-	0	0	100%	0.9333
4QAB_NAG_C_302	37%	42%	0.106	0.801	0.42	1.79	-	3	0	0	100%	0.9333
3H0C_NAG_A_794	100%	56%	0.021	0.995	0.61	1.08	-	1	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3PPS_NAG_B_760	100%	44%	0.028	0.993	0.57	1.57	-	3	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.